Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia

• Published in: Blood advances 2022-03, Vol.6 (5), p.1371-1380
• Main Authors: Fobare, Sydney, Kohlschmidt, Jessica, Ozer, Hatice Gulcin, Mrózek, Krzysztof, Nicolet, Deedra, Mims, Alice S., Garzon, Ramiro, Blachly, James S., Orwick, Shelley, Carroll, Andrew J., Stone, Richard M., Wang, Eunice S., Kolitz, Jonathan E., Powell, Bayard L., Oakes, Christopher C., Eisfeld, Ann-Kathrin, Hertlein, Erin, Byrd, John C.
• Format: Article
• Language: English
• Subjects: Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Mutation; Myeloid Neoplasia; Nucleophosmin; Phosphoric Monoester Hydrolases - genetics; Phosphoric Monoester Hydrolases - therapeutic use; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11 - genetics
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2021006242

Prognostic factors associated with chemotherapy outcomes in patients with acute myeloid leukemia (AML) are extensively reported, and one gene whose mutation is recognized as conferring resistance to several newer targeted therapies is protein tyrosine phosphatase non-receptor type 11 (PTPN11). The broader clinical implications of PTPN11 mutations in AML are still not well understood. The objective of this study was to determine which cytogenetic abnormalities and gene mutations co-occur with PTPN11 mutations and how PTPN11 mutations affect outcomes of patients treated with intensive chemotherapy. We studied 1725 patients newly diagnosed with AML (excluding acute promyelocytic leukemia) enrolled onto the Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology trials. In 140 PTPN11-mutated patient samples, PTPN11 most commonly co-occurred with mutations in NPM1, DNMT3A, and TET2. PTPN11 mutations were relatively common in patients with an inv(3)(q21q26)/t(3;3)(q21;q26) and a normal karyotype but were very rare in patients with typical complex karyotype and core-binding factor AML. Mutations in the N-terminal SH2 domain of PTPN11 were associated with a higher early death rate than those in the phosphatase domain. PTPN11 mutations did not affect outcomes of NPM1-mutated patients, but these patients were less likely to have co-occurring kinase mutations (ie, FLT3-ITD), suggesting activation of overlapping signaling pathways. However, in AML patients with wild-type NPM1, PTPN11 mutations were associated with adverse patient outcomes, providing a rationale to study the biology and treatment approaches in this molecular group. This trial was registered at www.clinicaltrials.gov as #NCT00048958 (CALGB 8461), #NCT00899223 (CALGB 9665), and #NCT00900224 (CALGB 20202). •Patients with N-terminal SH2 domain PTPN11 mutations had an early death (